Corticosterone (CORT) induced Depression Model Development Service
Are you currently facing long drug development cycles, difficulty in developing clinically relevant animal models, or challenges in understanding the complex neurobiological mechanisms of your therapeutic candidates? Our Corticosterone (CORT)-induced depression model development service helps you accelerate drug discovery, obtain high-quality preclinical data, and elucidate the mechanism of action of your compound through advanced in vivo pharmacology and biomarker analysis.
The CORT-induced depression model is a widely recognized and well-validated preclinical tool used to investigate the neurobiological basis of Major Depressive Disorder (MDD). It simulates the chronic hypercortisolemia observed in a significant portion of depressed patients. Published literature consistently demonstrates that sustained CORT exposure leads to a constellation of depression-like symptoms in rodents, including anhedonia and behavioral despair, thereby providing a robust platform for testing novel therapeutic agents.
How Our CORT-Induced Depression Model Development Service Can Assist Your Project
At Creative Bioabs, we provide a robust and reliable platform to support your CNS drug discovery program. Our service is designed to deliver high-quality, reproducible data that will inform your decision-making and accelerate your preclinical pipeline. We help you move from hypothesis to proof-of-concept by providing a powerful model for screening and validating novel antidepressants. Our core capabilities include the flexible development of CORT models, comprehensive behavioral and molecular analysis, and expert data interpretation.
Discover How We Can Help - Request a Consultation
Workflow
The CORT-induced depression model development service follows a streamlined, multi-step process designed for maximum efficiency and scientific rigor.
| Required Starting Materials |
Compound Information: A detailed description of the therapeutic compound, including its molecular formula, and desired route of administration. Study Goals: A clear outline of your research objectives, such as a desire to screen for antidepressant efficacy or to investigate a specific mechanism of action. |
| Final Deliverables |
Comprehensive Study Report: A detailed report containing all experimental procedures, raw data, statistical analysis, and a professional interpretation of the results. Raw Data Files: Complete raw data sets from all behavioral and molecular analyses for your own records and future use. Summary Presentation: A concise summary of the key findings, perfect for internal team meetings or stakeholder presentations. |
| Estimated Timeframe | The typical timeframe for a standard CORT-induced depression study ranges from 6 to 10 weeks, depending on the complexity of the compound and the number of endpoints requested. |
Why Choose Us?
Our deep expertise and commitment to scientific excellence set us apart. We provide a service that is not just a tool, but a collaborative partnership aimed at accelerating your success. Published data confirm that our models are robust and provide highly reproducible results, minimizing risk and maximizing the value of your research investment.
Experience the Advantage - Get a Quote Today
Customer Reviews
- Using CBL's CORT-induced depression model in our research has significantly improved our ability to validate lead compounds. The data on behavioral despair was incredibly clean and consistent across cohorts.
- The level of detail in the molecular analysis from CBL's service allowed us to definitively prove our compound's effect on neuroinflammation. It streamlined our preclinical validation and saved us months of work.
- We initially compared the CORT model to a chronic stress model, and the reproducibility of CBL's CORT service was far superior. It's now our go-to for antidepressant screening due to its stability and predictive validity.
Corticosterone (CORT)-Induced Depression Model
The CORT-induced depression model directly mimics this pathological state by administering exogenous corticosterone, creating a reliable and reproducible model of depression-like symptoms. This pharmacological approach avoids the variability often seen in stress-based models, providing a powerful, stable tool for drug screening and mechanistic studies.
Our expertise extends beyond simple behavioral screening. The CORT-induced model is an ideal platform for elucidating the mechanisms of action of novel therapeutics. We can provide a deeper dive into the neurobiological underpinnings of your compound's effects, investigating:
| Assays | Description |
| Neurogenesis | Quantifying new neuronal growth in the hippocampus to determine your compound's ability to reverse stress-induced neuronal atrophy. |
| Synaptic Plasticity | Analyzing changes in key synaptic proteins to understand how your compound may restore neural circuit function. |
| Neuroinflammation | Measuring pro-inflammatory cytokines and other markers to assess the role of neuroinflammation in your compound's efficacy. |
| Oxidative Stress & Apoptosis | Investigating the role of oxidative stress and programmed cell death in the CNS, mechanisms known to be involved in CORT-induced mood disorders. |
| Sleep Disturbances | Assessing co-morbid sleep-related phenotypes using technologies like electroencephalography (EEG), offering a more complete picture of your compound's therapeutic potential. |
What We Can Offer
- Unparalleled Expertise: Our team consists of seasoned CNS specialists with over 20 years of experience in drug discovery. We offer deep scientific knowledge and strategic guidance to ensure the success of your project.
- Customized and Flexible Solutions: We provide fully customized CORT model protocols, tailoring every detail from animal strain and administration route to a diverse range of behavioral and molecular endpoints, to perfectly align with your specific research objectives.
- Precision and Reproducibility: Our models are meticulously developed and validated to minimize variability and deliver highly reproducible results. This ensures the data you receive is reliable and can confidently inform critical decisions in your drug development process.
- Comprehensive Endpoints: We offer a full suite of readouts, including behavioral tests for anhedonia and despair, as well as in-depth molecular analyses for neurogenesis, neuroinflammation, and oxidative stress, providing a complete picture of your compound's efficacy.
- Expert Data Interpretation: We don't just provide data; we provide insights. Our team offers expert analysis and interpretation, helping you understand the implications of your results and guiding your next steps.
- Streamlined Project Management: We manage the entire process from start to finish, providing clear communication and timely updates to ensure a smooth, efficient, and transparent collaboration.
Related Services
To further support your CNS drug discovery program, we recommend the following complementary services:
- Target Identification & Validation
- Compound Screening & Profiling
- Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
- Neuroinflammation Research Models
FAQs
Q How do your models compare to stress-induced models like Chronic Mild Stress (CMS)?
Q Can you help us determine the optimal dose and administration route for our study?
We are ready to provide detailed information, answer your questions, and discuss your specific project needs.
Contact Our Team for More Information and to Discuss Your Project.
- Mouse Anti-SCN5A Monoclonal Antibody (CBP708) (Cat#: NAB-0720-Z2720)
- iNeuMab™ Mouse Anti-EFNB2 Monoclonal Antibody (CBP1159) (Cat#: NAB-0720-Z4396)
- iNeuMab™ Rabbit Anti-LRRK2 Monoclonal Antibody (CBP1887) (Cat#: NAB-08-PZ735)
- iNeuMab™ Anti-F-Spondin/SPON1 Antibody, Clone 3F4 (Cat#: NRZP-0822-ZP4740)
- iNeuMab™ Mouse Anti-LRP1 Monoclonal Antibody (CBP3363) (Cat#: NAB-0720-Z6479)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Rabbit Anti-Alpha-synuclein (CBP1631) (Cat#: NAB-08-PZ079)
- Mouse Anti-Human α-Synuclein Phospho (Tyr39) (CBP3706) (Cat#: NAB201250LS)
- Mouse Microglia from C57BL/6 (Cat#: NCL-21P6-082)
- Rat Schwann Cells RSC96, Immortalized (Cat#: NCL-2108P21)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Human Astrocytes, Immortalized (Cat#: NCL-2105-P182-AM)
- iNeu™ Human Sensory Neurons (Cat#: NCL-2103-P62)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Mouse Retinal Ganglion Cell Line RGC-5 (Cat#: NCL2110P154)
- Mouse Microglia N9 (Cat#: NCL2110P073)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- App Rat amyloid beta (A4) precursor protein (App)(NM_019288) ORF clone, Untagged (Cat#: NEP-0421-R0053)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-NAGLU BBB Shuttle Protein (Cat#: NRZP-0423-ZP506)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
